OLMESARTAN 40mg. IP + HYDROCHLOROTHIAZIDE 12.5mg. IP

A potent antihypertensive combination drug for effective blood pressure management and cardiovascular protection. More effective than olmesartan medoxomil 40 mg alone in reducing both systolic and diastolic blood pressure in patients with moderate to severe hypertension. (Roberto Fogari, 2010) Demonstrates superior reductions in both seated diastolic blood pressure and seated systolic blood pressure compared to monotherapy. (Steven G Chrysant, 2004) A well-tolerated drug that exhibits significant blood pressure reductions of up to 26.8/21.9 mm Hg. (Steven G Chrysant, 2004) An effective and safe agent in managing blood pressure in individuals with mild-to-severe hypertension. (Lars Christian Rump, 2010) A viable treatment option for patients struggling to achieve recommended blood pressure goals with monotherapy. (Lars Christian Rump, 2010) Shows superior efficacy in lowering blood pressure compared to the regimen of benazepril plus amlodipine besylate in patients with stage 2 hypertension. (Dean J Kereiakes, 2007) Promotes the excretion of sodium and water, thereby reducing blood volume and decreasing blood pressure. Produces greater reductions in blood pressure than a range of antihypertensive agents including other angiotensin II receptor blockers. (Ruilope, 2008) Blocks the action of angiotensin II, a substance in the body that causes blood vessels to constrict. (Julie A Brousil, 2003) Acts synergistically to lower blood pressure more effectively than either drug alone. Lowers blood pressure and protects the heart and blood vessels from damage associated with hypertension. An effective, fast-acting, and well-tolerated antihypertensive agent. (Brunner, 2006) A beneficial antihypertensive agent especially for high-risk patients. (Stefano Omboni M. V., 2019) An effective and well-tolerated combination antihypertensive therapy that results in significant BP reductions and BP control. (Greathouse, 2006)